Synaptogenix Inc (SNPX)

[SF Wolf]

In the microcosm of the AD research field Neurotrope’s results are next up:

While shareholders in NTRP are counting down the days until the Ph2b study results are released there is another group that is highly interested in the outcome.

Dr. Alkon gave the Keynote address at the Sachs Neuroscience and Biopartnering & Investment Forum (3-27-17) to some two hundred plus attendees, many of whom were representatives of the largest Pharmaceutical companies in the world. The CEOs of a number of NTRP competitors were also there to give their own company presentations. (see attendee list at bottom)

By design the Sachs Forum was set up to connect businesses involved in AD and Parkinson disease research with Big Pharmas that are looking at what is in the development pipeline for possible partnerships or buyouts.

Representative of many major Investment Funds were likewise prospecting for promising companies.

The large and small players in the AD research field are vitally interested in their counterpart’s research and they all know NTRP is next in line for results. And they are all aware that if Dr. Alkon’s theories are validated and Byrostatin -1 shows efficacy the AD research field will undergo a massive shift in focus.

The Sachs Forum format allowed company CEOs to meet one on one with Pharma and Investment Fund reps. Neurotrope had a number of such meetings with some of the largest Pharma companies in the world.

If the Ph2b results are what we are hoping for I expect that Neurotrope will be swiftly approached by Big Pharma companies who will immediately understand the market implications for Bryostatin.

Sachs Neuroscience Biopartnering & Investment Forum (3-27-17):
Confirmed Attending Companies Include:
A C Binder Corp.
AbbVie, Inc.
Abingworth LLP
Agent Capital, LLC
Alpha Bronze
Amorsa Therapeutics, Inc.
Angel Investor
APS International
Arbor Pharmaceuticals, Inc.
Arix Bioscience
ASDERA
Assembly Biosciences
Athyrium Capital Management
Avanir Pharmaceuticals
Avicenna Ventures
Axial Biotherapeutics
Bigger Capital Fund, LP
Bishop Capital Management
Boehringer Ingelheim Venture USA, Inc.
BrainStorm Cell Therapeutics, Inc.
Brendan E. Cryan & Co. LLC
Cambridge Cognition Ltd.
Cantabio Pharmaceuticals, Inc.
CastleRock Management
CBT Advisors
Cipla New Ventures
Clarus Ventures, LLC
Cognition Therapeutics, Inc.
Cortexyme
CureDuchenne Ventures
Dabar Investment Associates
Daiichi Sankyo, Inc.
Dawson James Securities, Inc.
Deca Ventures
Defined Health, a Cello Health business
Delwar Capital
Edison Investment Research
Eli Lilly and Co.
Embera NeuroTherapeutics, Inc.
Enso Ventures
Erydel
ESC Advisors
Exscientia Ltd.
F. Hoffmann La Roche Ltd.
First Republic Investment Management?
Flagship Ventures
Fountain Healthcare Partners
Fraser Finance
FreeMind Group
Goodwin Procter LLP
Hercules Technology Growth Capital, Inc.
Hereditary Neuropathy Foundation
ICR, Inc.
Johnson & Johnson
Katalyst Securities, LLC
KemPharm, Inc.
K-PAX Pharmaceuticals, Inc.
Landmark Family Office
Lauren Sciences LLC & Maya Sciences LLC
Lexington Capital Management
Little Gem Life Sciences
Lonza Walkersville, Inc.
Loop Capital Markets
Lysosomal Therapeutics, Inc.
M3 Biotechnology, Inc.
Mavericks Capital
MedPro Investors, LLC
Merck & Co., Inc.
Mergermarket
Mid Atlantic Bio Angels
Minoryx Therapeutics S.L.
Mizuho Bank
Momentum Biotech
MP Healthcare Venture Management, Inc.
NeuroRx, Inc.
NeuroTherapia, Inc.
Neurotrope Bioscience, Inc.
New Enterprise Associates
New Frontier Capital, LP
New York Ventures
Nexeon Medsystems, Inc.
NI Research, Inc.
Noble Life Science Partners
NSIP LLC
Occidental Group
Oppenheimer & Co. Inc.
Origenis GmbH
Oryzon Genomics SA
P4G Capital
Park Avenue Capital?
Parkfield Fund LLC
Perseverance Capital
Pfizer, Inc.
Pharmasum Therapeutics AS
PJT Partners
Probiodrug AG
ProMIS™ Neurosciences, Inc.
ProPhase
Purdue Pharma L.P.
Quartet Medicine
Queen Mary University London
Raman Health Technologies, S.L.
Remiges Ventures
Sachs Associates Ltd.
SalubRx Therapeutics, Inc.
Sanofi
Shadow Lake Group, Inc.
Shaw Strategic Capital LLC
Stanphyl Capital
SternAegis Ventures
Sternberg Investments
Sunovion Pharmaceuticals, Inc.
SunRegen Healthcare AG
Syncrosome
Syzygy Therapeutics
T3D Therapeutics, Inc.
Tanaka Capital Management
The Alzheimer's Drug Discovery Foundation
The Astrologers Fund, Inc.
The Center for Performance Investing
The Michael J. Fox Foundation
TikoMed AB
TS Family Office
Union Square Advisors
vasopharm GmbH
Vector Resource Funds
Vista Point Capital
WallachBeth Capital
WBB Securities, LLC
Wells Fargo Advisors
WestPark Capital
Wotczak Group
YLM2012 Trust
Yorkville Advisors, LLC
Yumanity Therapeutics
YunTai Fund USA Office


http://www.sachsforum.com/2nbpi-attendees.html